Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri

ERKEKOĞLU, ÜLFET PINAR; BAYDAR, Terken; Şahin, Gönül

Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri

ÜLFET PINAR ERKEKOĞLU, (Hacettepe Üniversitesi, Eczacılık Fakültesi, Farmasötik Toksikoloji Anabilim Dalı, Ankara, Türkiye)

Terken BAYDAR, (Hacettepe Üniversitesi, Eczacılık Fakültesi, Farmasötik Toksikoloji Anabilim Dalı, Ankara, Türkiye)

Gönül ŞAHİN (Hacettepe Üniversitesi, Eczacılık Fakültesi, Farmasötik Toksikoloji Anabilim Dalı, Ankara, Türkiye)

Türk Geriatri Dergisi

4 2

Yıl: 2008 Cilt: 11 Sayı: 3 Sayfa Aralığı: 151 - 168 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri

Öz:

Obezite günümüzde geriatrik popülasyon dahil toplumun tümünü ilgilendiren önemli bir sağlık sorunudur. Yaşla beraber gelen aşırı kilo/obezite veya obezitenin ileri yaşlarda da devam etmesi bireyin kalitesiz bir hayat sürdürmesine ve birçok sağlık probleminin ortaya çıkmasına veya varolan sağlık sorunlarının şiddetlenmesine neden olur. Yaşlıların kilo vermek için diyet yapması ve fiziksel aktiviteleri artırmaları gerekmektedir. Diğer taraftan, yaşlılar gençlere göre herbal preparatları kullanmaya daha fazla eğilim gösterirler. Fazla kilo sorununu çözmek için kullanılan bitkisel preparatlar ve gıda destekleyicileri ise ileri yaşlarda önemli toksikolojik sonuçlar doğurabilir. Bu derlemede yaşlılarda obezite tedavisinde herbal preparatların (efedra, kafein vb) ve gıda destekleyicilerin (krom pikolinat, chitosan gibi) kullanımının olası toksikolojik sonuçları tartışılacaktır.

Anahtar Kelime: Yaşlı Diyet destekleri Toksikoloji Geriatri Obezite Bitkisel preparasyonlar

Konular: Cerrahi

Evaluation of obesity treatment approaches in geriatric group from toxicological aspect-I: Herbal preparations and food suplements

Öz:

Obesity is an important health problem that concerns the whole society including geriatric population. Weight gain by aging or obesity persistance in the old age causes a poor quality life, brings health problems or causes intensity in the existing health matters. Elderly people should be on diet and make physical exercise in order to lose weight. On the other hand, elderly people tend to use herbal preparates more than younger ones. The use herbal preparates and food supplements to solve the overweight problem in old age may cause important toxicological outcomes. In this review the toxicological outcomes of the usage of herbal praparates (ephedra, cafein etc.) food supplements (chromium picollinate, chitosan, etc) in elderly for obesity terapy will be discussed.

Anahtar Kelime: Obesity Plant Preparations Aged Dietary Supplements Toxicology Geriatrics

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Sellers EM. Geriatric Clinical Pharmacology in Principles of Medical Pharmacology. H Kalant, WHE Roschlau, EM Sellers Eds. 4.Bask›, Oxford University Pres Inc, New York, 1985; pp: 807-17.
2. Thornburg JE. Geriontologic Pharmacology in Human Pharmacology Molecular-to-clinic. LB Wingard, TM Brody, J Larner, A Schwarz Eds. Mosby-Year Book Inc, St. Louis, Missoruri, 1991; pp: 851-56.
3. şahin G, Baydar T, Aydın S. Yaşlılık ve yaşlılıkta güvenli ilaç kullanımı. Yeni Türkiye Dergisi 2001; 40: 1087-98.
4. Clinical guideline 43: Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. National Institute for Health and Clinical Excellence. London, U.K., 2006; pp: 1-8.
5. Obesity: preventing and managing the global epidemic. World Health Organization Technical report series 894: Geneva, World Health Organization, 2000; pp: 1-10.
6. Villareal DT, Apovian CM, Kushner RF, Klein S; American Society for Nutrition; NAASO, The Obesity Society. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Obes Res. 2005; 13:1849-63.
7. Elia M. Obesity in the elderly. Obes Res 2001; (Suppl 4):244S 248S.
8. Lehmann AB, Bassey EJ. Longitudinal weight changes over four years and associated health factors in 629 men and women aged over 65. Eur J Clin Nutr. 1996; 50:6-11.
9. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286:1195-200.
10. Gallagher Camden S, Gates J. Obesity: changing the face of geriatric care. Ostomy Wound Manage 2006;52:36-8, 40-4.
11. Arterburn DE, Crane PK, Sullivan SD. The coming epidemic of obesity in elderly Americans. J Am Geriatr Soc 2004; 52: 1907-12.
12. Wallace JI, Schwartz RS. Involuntary weight loss in elderly outpatients: recognition, etiologies, and treatment. Clin Geriatr Med 1997; 13:717-35.
13. Ara R, Brennan A. The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries. Obes Rev 2007; 8:363-71.
14. Baumgartner RN, Wayne SJ, Waters DL, Janssen I, Gallagher D, Morley JE. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res 2004;12:1995-2004.
15. Horber FF, Gruber B, Thomi F, Jensen EX, Jaeger P. Effect of sex and age on bone mass, body composition and fuel metabolism in humans. Nutrition 1997; 13:524-34.
16. Zamboni M, Mazzali G, Zoico E, et al. Health consequences of obesity in the elderly: a review of four unresolved questions. Int J Obes (Lond) 2005; 29:1011-29.
17. Zoico E, Di Francesco V, Guralnik JM, et al. Physical disability and muscular strength in relation to obesity and different body composition indexes in a sample of healthy elderly women. Int J Obes Relat Metab Disord 2004; 28:234-41.
18. Dominguez LJ, Barbagallo M. The cardiometabolic syndrome and sarcopenic obesity in older persons. J Cardiometab Syndr 2007; 2:183-9.
19. Chau D, Cho LM, Jani P, St Jeor ST. Individualizing recommendations for weight management in the elderly. Curr Opin Clin Nutr Metab Care 2008; 11:27-31.
20. Jensen GL, Rogers J. Obesity in older persons. J Am Diet Assoc 1998; 98:1308-11.
21. Finer N. Obesity. Clin Med 2003; 3:23-7.
22. Rössner S. Obesity in the elderly--a future matter of concern? Obes Rev 2001; 2:183-8.
23. Frishman WH. Epidemiology, pathophysiology, and management of isolated systolic hypertension in the elderly. Am J Med. 1991; 90:14S-20S.
24. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 2007;113:134-53.
25. Ho RC, Niti M, Kua EH, Ng TP. Body mass index, waist circumference, waist-hip ratio and depressive symptoms in Chinese elderly: a population-based study. Int J Geriatr Psychiatry 2008, 23:401-8.
26. Ruelaz AR, Diefenbach P, Simon B, Lanto A, Arterburn D, Shekelle PG. Perceived barriers to weight management in primary care-perspectives of patients and providers. J Gen Intern Med 2007; 22:518-22.
27. Blake EW. Pioglitazone hydrochloride/glimepiride. Drugs Today (Barc) 2007; 43:487-97.
28. Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin 2007; 23:945-52.
29. Green JB, Feinglos MN. Are sulfonylureas passé? Curr Diab Rep 2006; 6:373-7.
30. Eichling PS, Sahni J. Menopause related sleep disorders. J Clin Sleep Med. 2005; 1(3):291-300.
31. Mahady GB, Fabricant D, Chadwick LR, Dietz B. Black cohosh: an alternative therapy for menopause? Nutr Clin Care 2002; 5:283-9.
32. Mahady GB. Black cohosh (Actaea/Cimicifuga racemosa): review of the clinical data for safety and efficacy in menopausal symptoms. Treat Endocrinol 2005; 4:177-84.
33. Stefanick ML. Estrogen, progestogens and cardiovascular risk. J Reprod Med 1999; 44:221-6.
34. Espeland MA, Stefanick ML, Kritz-Silverstein D, et al. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. J Clin Endocrinol Metab 1997;82:1549-56.
35. van Seumeren I. Weight gain and hormone replacement therapy: are women's fears justified? Maturitas 2000; 34 (Suppl 1):S3-8.
36. Marti A, Martinez JA. Genetics of obesity: gene x nutrient interactions. Int J Vitam Nutr Res 2006; 76:184-93.
37. Schümann K, Classen HG, Hages M, Prinz-Langenohl R, Pietrzik K, Biesalski HK. Bioavailability of oral vitamins, minerals, and trace elements in perspective. Arzneimittelforschung 1997; 47:369-80.
38. Villar HC, Saconato H, Valente O, Atallah AN. Thyroid hormone replacement for subclinical hypothyroidism Cochrane Database Syst Rev. 2007; (3):CD003419.
39. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002;8:457-69.
40. Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmächer T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. Psychiatr Res 2003; 37:193-220.
41. Fava M. Weight gain and antidepressants. Clin Psychiatry 2000; 61 Suppl 11:37-41.
42. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999;100:3-16.
43. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21:911-36.
44. Erduran E, Aslan Y, Gedik Y, Orhan F. A randomized and comparative study of intravenous immunoglobulin and mega dose methylprednisolone treatments in children with acute idiopathic thrombocytopenic purpura. Turk J Pediatr 2003; 45:295-300.
45. Gener›c Name: Predn›solone Solut›on/Syrup - Oral Brand Name( s): Orapred, Pediapred, Prelone. Last Editorial Review: 3/2/2005. Available online at: http://www.medicinenet. com/prednisolone_solutionsyrup-oral/article.htm. Erişim tarihi: Ocak 2008.
46. Kimmons JE, Blanck HM, Tohill BC, Zhang J, Khan LK Multivitamin use in relation to self-reported body mass index and weight loss attempts. MedGenMed 2006;8 :3.
47. State of Arkansas. The Impact of Obesity: Economics, Health, Prevention & Treatment. Presented by Obesity Task force, 2000. Available online at: http://www.brfss.arkansas. gov/pdf/obesity_report.pdf. Erişim tarihi: Ocak 2008.
48. Behn A, Ur E. The obesity epidemic and its cardiovascular consequences. Curr Opin Cardiol 2006; 21:353-60.
49. Banerjee S, Peterson LR.Myocardial metabolism and cardiac performance in obesity and insulin resistance. Curr Cardiol Rep 2007; 9:143-9.
50. Peterson LR. Obesity and insulin resistance: effects on cardiac structure, function, and substrate metabolism. Curr Hypertens Rep 2006; 8:451-6.
51. Lean ME. Pathophysiology of obesity. Proc Nutr Soc 2000;59:331-6.
52. Cabrera MA, Gebara OC, Diament J, Nussbacher A, Rosano G, Wajngarten M. Metabolic syndrome, abdominal obesity, and cardiovascular risk in elderly women. Int J Cardiol 2007; 114:224-9.
53. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice constituted by representatives of nine societies and by invited experts, 2007. Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 2):E1-40.
54. Després JP. Cardiovascular disease under the influence of excess visceral fat. Crit Pathw Cardiol 2007; 6:51-9.
55. Aronne LJ. Classification of obesity and assessment of obesityrelated health risks. Obes Res 2002; 10 (Suppl 2):105S-115S.
56. Nugent C, Younossi ZM. Evaluation and management of obesity- related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 432-41.
57. Marchesini G, Marzocchi R.Metabolic syndrome and NASH. Clin Liver Dis 2007; 11:105-17, ix.
58. Shaffer EA. Gallstone disease: Epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 2006; 20:981-96.
59. Formiguera X, Cantón A. Obesity: epidemiology and clinical aspects. Best Pract Res Clin Gastroenterol 2004; 18:1125-46.
60. Lagergren J. Body measures in relation to gastro-oesophageal reflux. Gut 2007; 56:741-2.
61. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007; 132: 2208-25.
62. Nguyen S, Hsu CY. Excess weight as a risk factor for kidney failure. Curr Opin Nephrol Hypertens 2007; 16:71-6.
63. Mistry T, Digby JE, Desai KM, Randeva HS. Obesity and prostate cancer: a role for adipokines. Eur Urol 2007; 52:46-53.
64. Amling CL. Relationship between obesity and prostate cancer. Curr Opin Urol 2005; 15:167-71.
65. Nelson EC, Evans CP, Lara PN Jr. Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev 2007; 33:299-313.
66. Noumoff JS, Faruqi S. Endometrial adenocarcinoma. Microsc Res Tech 1993; 25:246-54.
67. Ruhl C, Fox G, Sinclair BP, Stamps DC, Tabloski PA, Zurakowski T. Caring for older women: Nurses face new challenges with this increasingly active and vibrant population. AWHONN Lifelines 2006;10:298-304.
68. Schuster SR, Tabba M, Sahota P.Relationship between the cardiometabolic syndrome and obstructive sleep apnea. Cardiometab Syndr 2006; 1:204-8.
69. Van Meerhaeghe A, André S, Gilbert O, Delpire P, Moscariello A, Velkeniers B. Respiratory consequences of obesity--an overview. Acta Clin Belg. 2007; 62:170-5.
70. Christensen R, Bartels EM, Astrup A, Bliddal H. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis 2007; 66:433-9.
71. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol.2007; 44:62-9.
72. Walker-Bone KE, Palmer KT, Reading I, Cooper C.Soft-tissue rheumatic disorders of the neck and upper limb: prevalence and risk factors. Semin Arthritis Rheum 2003; 33:185-203.
73. Harney D, Patijn J. Meralgia paresthetica: diagnosis and management strategies. Pain Med 2007; 8:669-77.
74. Bigal ME, Lipton RB, Holland PR, Goadsby PJ. Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 2007; 68:1851-61.
75. Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol. 2007; 56:901-1.
76. Lean ME. Pathophysiology of obesity. Proc Nutr Soc 2000;59:331-6.
77. Weiss JR, Moysich KB, Swede H.Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:20-6.
78. Balon R. Mood, anxiety, and physical illness: body and mind, or mind and body? Depress Anxiety 2006; 23:377-87.
79. The Merck Manual of Geriatrics. Section 8. Metabolic and Endocrine Disorders Chapter 62. Obesity. Available online at: http://www.merck.com/mkgr/mmg/tables/62t1.jsp. Erişim tarihi: Ocak 2008.
80. Institute of Medicine. The role of nutrition in maintaining health in the nation’s elderly: evaluating covarage of nutrition services for the Medicare population. Washington, DC, National Academic Press, 2000; pp: 1-2.
81. DiMaria-Ghalili RA, Amella E. Nutrition in older adults. Am J Nurs. 2005; 105:40-50.
82. Chau D, Cho LM, Jani P, St Jeor ST. Individualizing recommendations for weight management in the elderly. Curr Opin Clin Nutr Metab Care 2008; 11:27-31.
83. Connor H, Annan F, Bunn E, et al; Nutrition Subcommittee of the Diabetes Care Advisory Committee of Diabetes UK. The implementation of nutritional advice for people with diabetes. Diabet Med. 2003; 20:786-807.
84. Johnson DK, Wilkins CH, Morris JC. Accelerated weight loss may precede diagnosis in Alzheimer disease. Arch Neurol. 2006; 63:1312-7.
85. Jensen GL. Obesity and functional decline: epidemiology and geriatric consequences. Clin Geriatr Med. 2005; 21:677-87.
86. Rizvi AA. The role of inflammation in diabetes and its complications. South Med J 2006; 99:8-9.
87. Binder EF, Schechtman KB, Ehsani AA, Steger-May K, Brown M, Sinacore DR, Yarasheski KE, Holloszy JO. Effects of exercise training on frailty in community-dwelling older adults: results of a randomized, controlled trial. J Am Geriatr Soc 2002; 50(12):1921-8.
88. Gostic CL. The crucial role of exercise and physical activity in weight management and functional improvement for seniors. Clin Geriatr Med 2005; 21:747-56, vii.
89. US Department of Agriculture. Center for Nutrition Policiy and Promotion. In the Matter of Nutrition and Aging: Leading a Healthy, Active Life. 2000 millenium Lecture Symposium. 28 September, 2000. Available at: http://www.cnpp.usda. gov/Publications/OtherProjects /SymposiumNutritionAndAging. pdf. Erişim tarihi: Ocak 2008.
90. Jensen GL, Rogers J. Obesity in older persons. Am Diet Assoc 1998; 98:1308-11.
91. Wing RR. Behavioral interventions for obesity: recognizing our progress and future challenges. Obes Res 2003; 11 (Suppl):3S-6S.
92. Sugerman, HJ, DeMaria, EJ, Kellum, JM, Sugerman, EL, Meador, JG, Wolfe, LG. Effects of bariatric surgery in older patients Ann Surg 2004; 240:243-47.
93. St. Peter, SD, Craft, RO, Tiede, JL, Swain, JM. Impact of advanced age on weight loss and health benefits after laparoscopic gastric bypass Arch Surg 2005; 140:165-8.
94. Sosa, JL, Pombo, H, Pallavicini, H, Ruiz-Rodriguez, M. Laparoscopic gastric bypass beyond age 60. Obes Surg 2004; 14:1398-401.
95. Drugs and Supplements. Ephedra (Ephedra Sinica/Ma Huang) monograph. Last Updated: may 1, 2006. Available at: http://www.mayoclinic.com/health/ephedra/NS_patient-ephedra. 96. Sales of Supplements Containing Ephedrine Alkaloids (Ephedra) Prohibited. Available at: http://www.fda.gov/oc/initiatives/ ephedra/february2004/. Erişim tarihi: Ocak 2008.
97. Weintraub J. Adverse Effects of Botanical and Non-Botanical Ephedrine Products 1997. Available at: http://www.hsph.harvard. edu/Organizations/DDIL/ephedrine.html.
98. Specific dangerous drugs included in Schedule IV. Provided by montana legislative services. Available at: http://data.opi.state. mt.us/bills/mca/50/32/50-32-229.
99. FDA News. For Immed›ate Release. P04-17. February 6, 2004. FDA Issues Regulation Prohibiting Sale of Dietary Supplements Containing Ephedrine Alkaloids and Reiterates Its Advice That Consumers Stop Using These Products. Available at: http://www.fda.gov/bbs/topics/NEWS/2004/ NEW01021.html. Eriflim tarihi: Ocak 2008.
100. Food and Drug Administration. Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk. The Federal Register 2004; Vol 69, No. 28:6787-6854. Available at: http://fr. cos.com/cgi-bin/getRec?id=20040211a 160http:// fr.cos.com/ cgi-bin/getRec?id=20040211a160. Erişim tarihi: Ocak 2008.
101. Dwyer JT, Allison DB, Coates PM. Dietary supplements in weight reduction. J Am Diet Assoc 2005; 105:S80-6. 102. Joint Formulary Committee. British National Formulary, 47th edition. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2004; pp: 525-529.
103. Professional’s Handbook of Complementary and Alternative Medicines. Charles W. Fetrow and Juan R. Avila Eds. Springhouse Corporation, Springhouse, Pennsylvania, USA, 1999;pp: 103-107.
104. Gener›c Name: Ephedr›ne–Oral. Last updated: 3/2/2005. Available at: http://www.medicinenet.com/ephedrine-oral/page2. htm. Eriflim tarihi: fiubat 2008.
105. Ephedrine. Professional Information. Available at: http://www.drugs.com/ppa/ephedrine.html 106. Cupp MJ. Herbal remedies: adverse effects and drug interactions. Am Fam Physician 1999; 59:1239-45.
107. Bouchard N, Hoffman RS. Synephrine is not Neo-Synephrine. Mayo Clin Proc. 2004; 79:1589-90.
108. High Blood Pressure. Medications and supplements that can raise your blood pressure. Available at: http://www.mayocli- nic.com/health/blood-pressure/HI00053. Eriflim tarihi: fiubat 2008.
109. Plants containing Caffeine. Available at: http://museum. gov.ns.ca/poison/holly.htm. Eriflim tarihi: fiubat 2008.
110. Zhao LC, ANdrews K, Holden J, Brandt M, Spease C, Dwyer J, Picciano MF. Caffeine containing dietary Supplements. Available at: http://www.nal.usda.gov/fnic/foodcomp/Data/ Other/ EB04_CaffeineSupp.pdf. Eriflim tarihi: fiubat 2008.
111. Newton R, Broughton LJ, Lind MJ, Morrison PJ, Rogers HJ, Bradbrook ID. Plasma and salivary pharmacokinetics of caffeine in man. Eur J Clin Pharmacol 1981; 21:45-52.
112. The Pharmacogenetics and Pharmacogenomics Knowledge Database (PharmGKB).Caffeine. Available at:http://www. pharmgkb.org/do/serve?objId=464&objCls=DrugProperties# biotransformationData. Eriflim tarihi: fiubat 2008.
113. Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 2004; 61:857-72.
114. Graham TE, Rush JW, van Soeren MH. Caffeine and exercise: metabolism and performance. Can J Appl Physiol. 1994; 19:111-38.
115. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999; 51:83-133.
116. Verkhratsky A. Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons. Physiol Rev 2005; 85:201-79.
117. Dews PB. Comments on some major methodologic issues affecting analysis of the behavioral effects of foods and nutrients. Psychiatr Res 1982-1983; 17:223-5.
118. Pittler MH, Ernst E. Dietary supplements for body-weight reduction: a systematic review. Am J Clin Nutr 2004; 79: 529-36.
119. Greenway FL, Raum WJ, DeLany JP. he effect of an herbal dietary supplement containing ephedrine and caffeine on oxygen consumption in humans. J Altern Complement Med. 2000;6:553-5.
120. Schulman S. Addressing the potential risks associated with ephedra use: a review of recent efforts. Public Health Rep 2003;118: 487-92.
121. Leson CL, McGuigan MA, Bryson SM. Caffeine overdose in an adolescent male. J Toxicol Clin Toxicol 1988; 26:407-15.
122. Caffeine related disorders. Definition. Available at: http://www.minddisorders.com/Br-Del/Caffeine-related-disorders. html. Erişim tarihi: fiubat 2008.
123. Cedars-Sinai Medical Center. Gastroesophageal Reflux Disease (GERD). Available at: http://www.csmc.edu/pf_5543.html. Erişim tarihi: fiubat 2008.
124. Caffeine Overdose. Medical Encylopedia. Last updated: 4/4/2006. Updated by: Janeen R. Azare, PhD, MSPH, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. Review provided by VeriMed Healthcare Network. Available at: http://www.nlm.nih.gov/medlineplus/ ency/article/002579.htm. Erişim tarihi: fiubat 2008.
125. Mackay DC, Rollins JW. Caffeine and caffeinism. R Nav Med Serv. 1989; 75:65-7.
126. James JE, Stirling KP. Caffeine: a survey of some of the known and suspected deleterious effects of habitual use. Br J Addict. 1983; 78:251-8.
127. Rapuri PB, Gallagher JC, Kinyamu HK, Ryschon KL.Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes. Am J Clin Nutr 2001; 74:694-700.
128. Massey LK. Is caffeine a risk factor for bone loss in the elderly? Am J Clin Nutr 2001; 74:569-70.
129. Guar Gum. Available at: www.guargum.biz/guargum.html. Eriflim tarihi: fiubat 2008.
130. Blackwood AD, Salter J, Dettmar PW, Chaplin MF. Dietary fibre, physicochemical properties and their relationship to health. J R Soc Health. 2000; 120(4):242-7.
131. CyberColloids. Guar Gum. Available at: ttp://www.cybercolloids. net/library/jecfa/index.php?submit=showspecgum=addi tive -0765. Erişim tarihi: fiubat 2008.
132. Brown JC, Livesey G. Energy balance and expenditure while consuming guar gum at various fat intakes and ambient temperatures. Am J Clin Nutr 1994; 60:956-64.
133. Chan JKC, Wypyszyk V. A forgotten natural dietary fiber: psyllium mucilloid. Cereal Foods World 1988 33:919-922.
134. Mathur, D.P., B. Rangarajan, V. Gupta. 1990. Psyllium production and marketing in India. New Delhi: Oxford and IBH Pub. Co. pp: 167.
135. Mehta KG J, Gupta MR. Psyllium. Ind J Agron 1976;21:509-510.
136. Abraham ZD, Mehta T.Three-week psyllium husk supplementation: Effect on plasma cholesterol concentrations, fecal steroid excretion, and carbohydrate absorption in men. Am J Clin Nutr 1988; 47:67-74.
137. Lantner RR, Espiritu BR, Zumerchik P, Tobin MC. Anaphylaxis following ingestion of a psyllium-containing cereal. JAMA 1990; 264:2534-6.
138. Liebman B. The laxative that lowers cholesterol. Nutr. Action Health Letter 1988; 15:9.
139. Bell LP, Hectorn KJ, Reynolds H, Hunninghake DB. Cholesterol- lowering effects of soluble-fiber cereals as part of a prudent diet for patients with mild to moderate hypercholesterolemia. Am J Clin Nutr 1990; 52:1020-6.
140. Gener›c Name: Senna/Psyll›um Seed–Oral. Brand Name(s): Perdiem. Available At: http://www.medicinenet.com/sennapsyllium_ seed-oral/article.htm. Erişim tarihi: fiubat 2008.
141. Possible Interactions with: Psyllium. University of Maryland Medical Center Available At: http://www.umm.edu/altmed/ articles/psyllium-000976.htm.
142. Shara M, Ohia SE, Yasmin T, et al. Dose- and time-dependent effects of a novel (-)-hydroxycitric acid extract on body weight, hepatic and testicular lipid peroxidation, DNA fragmentation and histopathological data over a period of 90 days. Mol Cell Biochem 2003; 254:339-46.
143. Saito M, Ueno M, Ogino S, Kubo K, Nagata J, Takeuchi M. High dose of Garcinia cambogia is effective in suppressing fat accumulation in developing male Zucker obese rats, but highly toxic to the testis. Food Chem Toxicol. 2005; 43:411-9.
144. Yohimbe bark extract (Pausinystalia yohimbe Pierre ex Beille Rubiaceae). Last updated: December 01, 2006. Available at: http://www.nlm.nih.gov/medlineplus/druginfo/natural/ patient- yohimbe.html. Erişim tarihi: fiubat 2008.
145. Franz G. The senna drug and its chemistry. Pharmacology 1993; 1S:2-6.
146. Brusick D, Mengs U. Assessment of the genotoxic risk from laxative senna products. Environ Mol Mutagen 1997; 29:1-9.
147. Senna fact sheet. Senna. Alternative medicine. Created on: 03/30/2006. Available At: http://altmedicine.about.com/ od/completeazindex/a/senna.htm. Eriflim tarihi: fiubat 2008.
148. Senna. Drug Interactions. Available at: http://www.pccnaturalmarkets. com/health/3091001/.
149. MacLean, DB, Lu-Guang L. Increased ATP content/production in the hypothalamus may be a signal for energy-sensing of satiety: studies of the anorectic mechanism of a plant steroidal glycoside. Brain Research 2004; 1020: 1-11.
150. Avula B, Wang YH, Pawar RS, Shukla YJ, Schaneberg B, Khan I A. Determination of the appetite suppressant P57 in Hoodia gordonii plant extracts and dietary supplements by liquid chromatography/electrospray ionization mass spectrometry (LC-MSD-TOF) and LC-UV methods. J AOAC Int 2006;89: 606-611.
151. Hoodia: lose weight without feeling hungry? Consum Rep 2006; 71:49.
152. US Food and Drug Administration. "Warning Letter for Weight Loss Products 'TrimSpa Carb Blocker' and 'TrimSpa Fat Blocker”. March 26, 2004. Available at: http://www. cfsan.fda.gov/~dms/wl-ltr14.html. Erişim tarihi: fiubat 2008.
153. Habeck M. A succulent cure to end obesity. Drug Discov Today 2002; 7:280-1.
154. Lee RA, Balick MJ. Indigenous use of Hoodia gordonii and appetite suppression. Explore (NY) 2007; 3:404-6.
155. Lemaire PA, Adosraku RK. An HPLC method for the direct assay of the serotonin precursor, 5-hydroxytrophan, in seeds of Griffonia simplicifolia. Phytochem Anal. 2002; 13:333-7.
156. Rahman MK, Nagatsu T, Sakurai T, Hori S, Abe M, Matsuda M. Effect of pyridoxal phosphate deficiency on aromatic L-amino acid decarboxylase activity with L-DOPA and L-5-
hydroxytryptophan as substrates in rats. Jpn J Pharmacol 1982; 32:803-11.
157. Bouchard S, Bousquet C, Roberge AG. Characteristics of dihydroxyphenylalanine/
5-hydroxytryptophan decarboxylase activity in brain and liver of cat. J Neurochem 1981; 37:781-7.
158. Bouchard S, Roberge AG. Biochemical properties and kinetic parameters of dihydroxyphenylalanine--5-hydroxytryptophan decarboxylase in brain, liver, and adrenals of cat. Can J Biochem 1979; 57:1014-8.
159. Das YT, Bagchi M, Bagchi D, Preuss HG. Safety of 5-hydroxy- L-tryptophan. Toxicol Lett. 2004;150:111-22.
160. Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5- Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. Clin Psychopharmacol 1987; 7:127-37.
161. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice- drug interactions. Br J Clin Pharmacol 1998; 46:101-10.
162. Straughan JL. Grapefruit-drug interactions. Cardiovasc J S Afr. 2007; 18:39-40.
163. Paine MF, Oberlies NH. Clinical relevance of the small intestine as an organ of drug elimination: drug-fruit juice interactions. Expert Opin Drug Metab Toxicol 2007; 3:67-80.
164. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997; 33:103-21.
165. Mahdi JG, Mahdi AJ, Mahdi AJ, Bowen ID. The historical analysis of aspirin discovery, its relation to the willow tree and antiproliferative and anticancer potential. Cell Prolif 2006; 39:147-55.
166. loo AG, Miller DS. Ephedrine, caffeine and aspirin: "over-thecounter" drugs that interact to stimulate thermogenesis in the obese. Nutrition 1989; 5:7-9.
167. Dulloo AG, Miller DS. Aspirin as a promoter of ephedrine-induced thermogenesis: potential use in the treatment of obesity. Am J Clin Nutr 1987; 45:564-9.
168. Dulloo AG. Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. Int J Obes Relat Metab Disord 1993; 1:S35-40.
169. Spolarich AE, Andrews L. An examination of the bleeding complications associated with herbal supplements, antiplatelet and anticoagulant medications. J Dent Hyg 2007; 81:67.
170. Gerbino PP. Complications of alcohol use combined with drug therapy in the elderly. Am Geriatr Soc. 1982; 30(11 Suppl):S88-93.
171. Sweeney KR, Chapron DJ, Brandt JL, Gomolin IH, Feig PU, Kramer PA. Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation. Clin Pharmacol Ther. 1986; 40(5):518-24.
172. Hersh EV, Pinto A, Moore PA. Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther. 2007;29 (Suppl):2477-97.
173. Jones JI, Hawkey CJ. Physiology and organ-related pathology of the elderly: stomach ulcers. Best Pract Res Clin Gastroenterol 2001; 15:943-61.
174. Jenneck C, Juergens U, Buecheler M, Novak N. Pathogenesis, diagnosis, and treatment of aspirin intolerance. Ann Allergy Asthma Immunol 2007; 99:13-21.
175. Lip GY, Edmunds E, Beevers DG. Should patients with hypertension receive antithrombotic therapy? J Intern Med. 2001;249:205-14.
176. Plants Profile. Achillea millefolium L. Common Yarrow. Created on: 14/7/ 2001. Nat›ral Resources Conservation Center. United states Department of Agriculture. Available at: http:// www.plants.usda.gov/java/profile?symbol=ACMI2. Eriflim tarihi: fiubat 2008.
177. Benedek B, Kopp B. Achillea millefolium L. s.l. revisited: recent findings confirm the traditional use. Wien Med Wochenschr 2007; 157:312-4.
178. Final report on the safety assessment of Yarrow (Achillea millefolium) Extract. Int J Toxicol 2001; 2:79-84.
179. US Department of Health and Human Sciences. Public Health Sevice. September 2000. Agency for Toxic Substances and Disease Registry. Chromium. CAS#: 7440-47-3. ToxFAQs™ for Chromium. Last updated on: 09/11/2007. ASvailable at: http://www.atsdr.cdc.gov/tfacts7.pdf. Eriflim tarihi: fiubat 2008.
180. US Department of Health and Human Sciences. Public Health Sevice. SEptember 2000. Agency for Toxic Substances and Disease Registry. Toxicological Profile of Chromium. Available at: http://www.atsdr.cdc.gov/toxprofiles/tp7.pdf.
181. Jeejeebhoy KN. The role of chromium in nutrition and therapeutics and as a potential toxin. Nutr Rev 1999; 57:329-35.
182. Cohn LA, Dodam JR, McCaw DL, Tate DJ. Effects of chromium supplementation on glucose tolerance in obese and nonobese cats. Am J Vet Res 1999; 60:1360-3.
183. Fuhr JP Jr, He H, Goldfarb N, Nash DB. Use of chromium picolinate and biotin in the management of type 2 diabetes: an economic analysis. Dis Manag 2005; 8:265-75.
184. McCarty MF. High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy for type II diabetes. Med Hypotheses 1999; 52:401-6.
185. Brown RP, Gerbarg PL. Herbs and nutrients in the treatment of depression, anxiety, insomnia, migraine, and obesity. J Psychiatr Pract 2001; 7:75-91.
186. Dyck DJ. Dietary fat intake, supplements, and weight loss. Can J Appl Physiol 2000; 25:495-523.
187. Nestler JE, Jakubowicz D J, Reamer P, Gunn R D, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999; 40:1314–20.
188. Nestler JE, Jakubowicz DJ, Iuorno MJ. Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome. J Pediatr Endocrinol Metab 2000; 5:1295-8.
189. Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol 2001; 1: 335–339.
190. Head KA. Inositol hexaniacinate: a safer alternative to niacin. Alt Med Rev 1996; 1:176–84.
191. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature 2006; 444:854-9.
192. Murphy KG, Dhillo WS, Bloom SR. Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev. 2006; 27:719-27.
193. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20:805-75.
194. Matson CA, Reid DF, Ritter RC. Daily CCK injection enhances reduction of body weight by chronic intracerebroventricular leptin infusion. Am J Physiol Regul Integr Comp Physiol 2002; 282:R1368-73.
195. Mayo Clinic. Drugs and Supplements. Cholecystokinin. (Injection Route). Last updated: 1/7/2006. Available at: http:// www.mayoclinic.com/health/drug-information/DR600365. Eriflim tarihi: fiubat 2008.
196. Göpel C, Schmidt MH, Campanini M, Klein J. Breakdown of choline-containing phospholipids in rat brain during severe weight loss. Neurosci Let. 2002; 326:21-4.
197. PDR Health (Physicians Desk Top Reference). Herbals and Supplements. Choline. Available at: http://www.pdrhealth. com/drugs/altmed/altmed-mono.aspx?contentFileName= ame0336.xml&content Name=Choline&contentId =492. Eriflim tarihi: fiubat 2008.
198. Ni Mhurchu C, Dunshea-Mooij CA, Bennett D, Rodgers A. Chitosan for overweight or obesity. Cochrane Database Syst Rev 2005; 3:CD003892.
199. Razdan A, Pettersson D. Effect of chitin and chitosan on nutrient digestibility and plasma lipid concentrations in broiler chickens. Br J Nutr 1994; 72:277-88.
200. Beall J. Over-the-counter products for weight management. Ala Nurse 2007; 34:11-2.
201. Huang SS, Sung SH, Chiang CE. Chitosan potentiation of warfarin effect. Ann Pharmacother 2007; 41:1912-4.
202. Hendler SS, Rorvik D (eds). PDR for nutritional supplements. Montvale, NJ: Medical Economics; 2001; pp: 1-543
203. Thomas D. Seaweeds. The Natural History Museum, London, 2002; pp: 15.
204. Anonymous. Kelp diets can produce myxedema in iodine-sensitive individuals. JAMA 1975;233:9-10.
205. Shilo S, Hirsch HJ. Iodine-induced hyperthyroidism in a patient with a normal thyroid gland. Postgrad Med J 1986; 62:661-2.

APA	ERKEKOĞLU Ü, BAYDAR T, Şahin G (2008). Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri. , 151 - 168.
Chicago	ERKEKOĞLU ÜLFET PINAR,BAYDAR Terken,Şahin Gönül Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri. (2008): 151 - 168.
MLA	ERKEKOĞLU ÜLFET PINAR,BAYDAR Terken,Şahin Gönül Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri. , 2008, ss.151 - 168.
AMA	ERKEKOĞLU Ü,BAYDAR T,Şahin G Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri. . 2008; 151 - 168.
Vancouver	ERKEKOĞLU Ü,BAYDAR T,Şahin G Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri. . 2008; 151 - 168.
IEEE	ERKEKOĞLU Ü,BAYDAR T,Şahin G "Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri." , ss.151 - 168, 2008.
ISNAD	ERKEKOĞLU, ÜLFET PINAR vd. "Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri". (2008), 151-168.

APA	ERKEKOĞLU Ü, BAYDAR T, Şahin G (2008). Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri. Türk Geriatri Dergisi, 11(3), 151 - 168.
Chicago	ERKEKOĞLU ÜLFET PINAR,BAYDAR Terken,Şahin Gönül Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri. Türk Geriatri Dergisi 11, no.3 (2008): 151 - 168.
MLA	ERKEKOĞLU ÜLFET PINAR,BAYDAR Terken,Şahin Gönül Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri. Türk Geriatri Dergisi, vol.11, no.3, 2008, ss.151 - 168.
AMA	ERKEKOĞLU Ü,BAYDAR T,Şahin G Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri. Türk Geriatri Dergisi. 2008; 11(3): 151 - 168.
Vancouver	ERKEKOĞLU Ü,BAYDAR T,Şahin G Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri. Türk Geriatri Dergisi. 2008; 11(3): 151 - 168.
IEEE	ERKEKOĞLU Ü,BAYDAR T,Şahin G "Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri." Türk Geriatri Dergisi, 11, ss.151 - 168, 2008.
ISNAD	ERKEKOĞLU, ÜLFET PINAR vd. "Geriatrik grupta obezite tedavi yaklaşımlarının toksikolojik açıdan değerlendirilmesi-I: herbal preparatlar ve gıda destekleyicileri". Türk Geriatri Dergisi 11/3 (2008), 151-168.